Consistently, HNSCC patients with low signature scores demonstrated increased expended IGS scores, suggesting an effective response to anti-PD-1 therapy (Figures 5, 6A and Supplementary Table S3). The gene discussed is PDCD1; the disease is head and neck squamous cell carcinoma.